KB Home: Form 10-Q for the period ended Feb 29, 2024
Filed with the SEC on Apr 5, 2024 and accepted by EDGAR at Apr 5, 2024, 20:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-02-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-12-01 to 2024-02-29 | $1.47bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Income tax | 3 months2023-12-01 to 2024-02-29 | $36.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-12-01 to 2024-02-29 | $138.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-12-01 to 2024-02-29 | $1.76 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-12-01 to 2024-02-29 | $1.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-12-01 to 2024-02-29 | 78,264,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-12-01 to 2024-02-29 | $28.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-12-01 to 2024-02-29 | $9.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2023-12-01 to 2024-02-29 | $16.4m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2023-12-01 to 2024-02-29 | $50.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Total assets | At period end2024-02-29 | $6.68bn | us-gaap:Assets |
| Shareholders' equity | At period end2024-02-29 | $3.88bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-02-29 | 75,915,205 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000795266-24-000060. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.